Articles tagged "Immunosuppression"

2016 American Transplant Congress
Clinical Factors That Determine the Appropriateness of Early Steroid Withdrawal.
S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, D. Segev.
Johns Hopkins, Baltimore, MD.
Early steroid withdrawal (ESW) has been a popular option for recipients with low-immunological risk. However, no quantitative tools are available to assess the risk, i.e.…
2016 American Transplant Congress
Steroid Free Immunosuppression and Clinical Outcomes in Recipients of Deceased Donor Kidney Transplant with Positive Flow Cytometry Crossmatch.
O. Adebiyi, T. Taber, W. Goggins, D. Mishler, M. Yaqub, A. Sharfuddin.
Indiana University, Indianapolis.
Background: Positive flow cytometry crossmatch (FCXM) is considered a high immunologic risk for transplantation. Available studies reporting outcomes in positive FCXM kidney transplants were done…
2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.
B.-H. Shin, S. Ge, J. Choi, J. Kahwaji, A. Vo, A. Petrosyan, S. Jordan, M. Toyoda.
Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplant in HS patients. TCZ has anti-B cell and anti-inflammatory properties. We have reported its…
2016 American Transplant Congress
Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.
G. Spagnoletti, M. Salerno, V. Bianchi, N. Silvestrini, F. Apponi, J. Romagnoli.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction.Aim of this study was to evaluate the efficacy and safety of preemptive prophylaxis of CMV infection in kidney transplant recipients (KTx) receiving polyclonal antibodies…
2016 American Transplant Congress
Differences in Reported Barriers to Immunosuppression Adherence Among a Cohort of Pediatric Renal Transplant Recipients from the United States and Canada.
O. Bignall II,^1,2 A. Pai,² S. Amaral,³ S. Furth,³ N. Bergman,² J. Goebel,⁴ The TAKE-IT Study Investigators, B. Foster.⁵
¹Nephrology and Hypertension, Cincinnati Children's Hospital, Cincinnati, OH; ²Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital, Cincinnati, OH; ³Nephrology, The Children's Hospital of Philadelphia, Philadelphia, PA; ⁴Nephrology, Children's Hospital of Colorado, Aurora, CO; ⁵Nephrology, Montreal Children's Hospital, Montreal, QC, Canada.
Aim: The purpose of this study was to examine differences in reported barriers to immunosuppressant adherence (IA) between a cohort of pediatric renal transplant recipients…
2016 American Transplant Congress
Tool to Assess Risk of Non-Adherence in Renal Transplant Candidates.
T. Kaiser,¹ K. Daley,² L. Dick,² L. Deye,² N. Parrish,² J. Huff,² A. Govil,¹ B. Abu Jawdeh,¹ G. Mogilishetty,¹ R. Alloway,¹ E. Woodle.¹
¹Medicine, University of Cincinnati, Cincinnati; ²Transplant, University of Cincinnati Medical Center, Cincinnati, OH.
Nonadherence (NA) is likely the primary driver of late graft loss and was found to occur in 59% of renal transplant (RTx) patients at our…
2016 American Transplant Congress
Pharmacist Impact on Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, South Carolina.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to assess the impact of…
2016 American Transplant Congress
Prospective Randomized OPEN Trial Designed to Reduce the Incidence of Cytomegalovirus (CMV) Infection in DE NOVO Kidney Transplant Recipients Two-Year Results.
R. Esmeraldo, M. Oliveira, P. Pinheiro, C. Girao, T. Freitas.
Transplant, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil.
Introduction: CMV infection is a frequent complication following organ transplantation, and is associated with inferior long-term patient and graft survival. Here we report the results…
2016 American Transplant Congress
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.
S. Stead,¹ S. McInnes,² S. Kireta,³ P. Rose,¹ D. Rojas-Canales,³ S. Jesudason,³ S. Grey,⁴ R. Carroll,³ N. Voelcker,² P. Coates.^1,3
¹School of Medicine, University of Adelaide, Adelaide, Australia; ²Future Industries Institute, University of South Australia, Adelaide, Australia; ³CNARTS, Royal Adelaide Hospital, Adealide, Australia; ⁴Transplantation Immunology, Garvan Institute of Medical Research, Sydney, Australia.
Aims: Dendritic cells (DC) are the most potent antigen-presenting cell and are fundamental in the establishment of transplant tolerance. Targeting DC via the DC-SIGN receptor…
2016 American Transplant Congress
Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal.
C. Lefaucheur,¹ L. Hidalgo,² J. Reeve,² D. Viglietti,¹ C. Gosset,¹ O. Aubert,³ C. Ulloa,³ C. Legendre,³ D. Glotz,¹ P. Halloran,² A. Loupy.³
¹Saint-Louis Hospital, Paris, France; ²University of Alberta, Edmonton, Canada; ³Necker Hospital, Paris, France.
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft outcome. We investigated the effect of terminal complement inhibition (Eculizumab) in a cohort of…